Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
11 July 2019 - 6:07AM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology, today
announced that it intends to offer and sell shares of its common
stock in an underwritten public offering. In connection with this
offering, Eyenovia expects to grant the underwriters a 30-day
option to purchase up to an additional 15% of the shares of common
stock to be sold in the offering. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
Eyenovia intends to use the net proceeds from
the public offering, together with other available funds, for the
MicroProst and MicroPine clinical studies and for working capital
and general corporate purposes.
Oppenheimer & Co. Inc. is acting as sole
book-running manager for the offering. Ladenburg Thalmann
& Co. Inc. is acting as lead manager for the offering.
The offering is being made pursuant to a shelf
registration statement on Form S-3 (File No. 333-229365) that was
declared effective by the Securities and Exchange Commission (the
“SEC”) on February 12, 2019. A preliminary prospectus supplement
related to the offering will be filed with the SEC and will be
available on the SEC’s website, located at www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to the offering, when available, may also be
obtained from Oppenheimer & Co. Inc., Attention: Syndicate
Prospectus Department, 85 Broad Street, 26th Floor, New York, NY,
10004, by telephone at (212) 667-8055, or by email at
EquityProspectus@opco.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any offer or sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical
stage ophthalmic biopharmaceutical company developing a pipeline of
microdose therapeutics utilizing its patented piezo-print
technology. Eyenovia’s pipeline is currently focused on the
late-stage development of microdosed medications for mydriasis,
myopia progression, glaucoma and other eye diseases.
Forward-Looking Statements
Except for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things, market conditions, the satisfaction
of customary closing conditions for the proposed offering, the
Company’s expected use of the net proceeds from the public
offering, its need to raise additional capital even after this
financing, and other risks and uncertainties described in
Eyenovia’s filings with the SEC. Any forward-looking statements
speak only as of the date on which they are made, and except as may
be required under applicable securities laws, Eyenovia does not
undertake any obligation to update any forward-looking
statements.
Company Contact:Eyenovia, Inc.
John GandolfoChief Financial Officerjgandolfo@eyenoviabio.com
Investor Contact:The Ruth
GroupTram Bui / Alexander LoboPhone:
646-536-7035/7037tbui@theruthgroup.com / alobo@theruthgroup.com
Media Contact:The Ruth
GroupKirsten Thomas508-280-6592kthomas@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From May 2023 to May 2024